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Abstract
Glioblastoma is one of the most frequent primary brain tumours of the central nervous sys-
tem, with a poor survival time. With inefficient chemotherapy, it is urgent to develop new
strategies for tumour therapy. The present approach is based on the inhibition of cell prolifer-
ation using platinum nanoparticles (NP-Pt). The aim of the study was to evaluate and com-
pare the antiproliferative properties of NP-Pt and cisplatin against U87 and U118 glioma cell
lines and U87 tumour tissue. NP-Pt and cisplatin were incubated with U87 and U118 glioma
cells or administered directly into glioma tumour tissue. Cell morphology, the level of DNA
synthesis, the migration of cells, protein expression levels of proliferating cell nuclear anti-
gen (PCNA) and the level of DNA oxidation in glioma tumours were investigated. The results
showed that NP-Pt treatment of U87 and U118 glioma cells decreased the level of DNA syn-
thesis and the migration of cancer cells but also downregulated the level of PCNA protein
expression in tumour tissue. Furthermore, NP-Pt caused oxidative DNA damage in tumour
tissue to a higher degree than cisplatin. Consequently, NP-Pt can be considered as an
effective inhibitor of glioblastoma tumour cell proliferation. However, the mechanism of
action and potential side effects need to be elucidated further.
Background
Glioblastoma multiforme tumour (GBM) is the most frequent and malignant brain tumour
(WHO grade IV) in adults, with a poor prognosis. The etiologic features of this central nervous
tumour are still unknown. Therapeutic treatments based on radio- and chemotherapy do not
significantly improve the survival rates of patients diagnosed with glioma [1]. Only the radio-
therapy plus temozolomide improved the survival rates of glioblastoma patients. The major
drawbacks of glioma treatments are the rapid infiltrating growth of tumour tissue, the ability
to migrate and invasive tumour growth [2, 3]. Glioma cells are also able to degrade the extra-
cellular matrix, stimulate cell invasion signalling pathways and thus invade healthy brain tissue
[3]. Moreover, the proliferation of glioma cells is correlated with a high degree of tumour
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malignancy, which can be evaluated by measuring the protein expression of proliferating cell
nuclear antigen (PCNA) [4]. Despite the novel strategy of treatments based on surgical
resection and the combination of chemotherapy with radiotherapy, the main mechanisms of
invasion, proliferation and migration in tumour cells are still not well elucidated. A better
understanding of the proliferation and growth of glioma cells might offer a new therapeutic
strategy involving the use of a new type of bioactive molecules; nanoparticles. To increase the
efficiency of anticancer therapy, new approaches to the inhibition of cancer cell proliferation
and malignancy using nanostructures are under investigation [5]. Nanoparticles are defined as
small (<100 nm) particles with unique physicochemical properties. Recently, the application
of nanoparticles has been considered as a new approach for the treatment and diagnoses of
glioblastoma due to their catalytic activity, limited distribution of ions in the organism and
possibilities for accumulation in glioma cells. Thus, the process of forming platinum salts with
body fluids is very slow and restricted. Nanoparticles of noble metals, as NP-Pt, have a high
surface-to-volume ratio, and are ideally suited as catalysts. Comparing to bare materials,
NP-Pt require less energy activation than platinum metal. Moreover, NP-Pt catalyse chemical
reaction including hydrogen evolution reaction and separating water into oxygen and hydro-
gen. The antioxidative properties of NP-Pt, where NP-Pt inhibited hydrogen peroxide and
induced oxidative cellular damage in HepG26 have been demonstrated [6]. Moreover, NP-Pt
are able to cross the cell membrane and accumulate in glioma cells [7]. NP-Pt (99,999%) with
no coating and/or stabilization additives, like e.g. PVP, have larger active surface area making
nanoparticles more biologically active at lower doses [6] and consequently may affect their
antiproliferative activity.
Platinum nanoparticles (NP-Pt) showed dose-dependent toxicity against different types of
human cancer cells including breast MCF-7, liver HepG-2 [6], colorectal HT29 [8], lymphoma
U937 [9] and glioma U87 [6], U251 [10]. Moreover, NP-Pt combined with hadron cancer ther-
apy created DNA strand breaks and activated apoptosis in HT29 cancer cells [8]. The direct
interaction of NP-Pt with the double helix of DNA, the formation of DNA strand breaks and
consequent activation of the apoptosis pathway in cancer cells were also observed in U87 gli-
oma cells [6], Caco-2 [11], HT29 [12] colon carcinoma cells and C6 rat glioma [13]. Toxicity
investigations with the in vivo mice model, demonstrated that NP-Pt, but with size less that
1nm, induced the kidney injury after i.v. administration [14], and also can induce the mito-
chondria degradation of brain tissue samples, activation of apoptosis and reduced rate of the
brain cell proliferation [15]. However, these side effects had a minor influence on general
health parameters and were less toxic comparing to the side effect of cisplatin, including drug
resistance, haemolysis, nephrotoxicity, ototoxicity, hepatotoxicity and blood marrow damage
[16].
Despite increased numbers of scientific reports about a biointeraction between NP-Pt and
various lines of cancer cells, the effect of NP-Pt on the proliferation and migration of glioblas-
toma cells is still not well elucidated. Moreover, until now, there has been insufficient data
regarding the inhibition of proliferating cell nuclear antigen (PCNA) expression by NP-Pt at
U118 and U87 glioblastoma cells and tumour tissue. The direct comparison of antiproliferative
features of NP-Pt vs. cisplatin against U87 and U118 or any other glioblastoma cells line have
not been documented so far. Thus, this study was designed to compare the anti-proliferative
efficiency of two different sources of Pt against two genetically and morphological different
cell lines of glioblastoma—U87 and U118.
We hypothesized that because of unique physicochemical features of NP-Pt, nanoplatinum
may exert, different from cisplatin treatment, antiproliferative effects on U118 and U87 glio-
blastoma cells and tumour. The novel strategies of glioblastoma treatments are based on the
previous achievements, including chemotherapy, but also radiotherapy and very precise
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resection of glioblastoma tumour. According to clinicaltrails.gov, there are only three clinical
trials for glioblastoma treatment using nanotechnology, but only one of them have same
results from Phase I. Consequently, we suppose the presented approach provides some rele-
vant and novel results.
The objective of the present study was to determine the antiproliferative efficiency of
NP-Pt, in comparison with cisplatin, on glioblastoma cell lines and tumour tissue.
Materials and methods
Ethics statement
The experimental procedures were performed in accordance with Polish legal regulations con-
cerning experiments on animals (Dz. U. 05.33.289). The experimental protocols were accepted
by the III Local Ethics Commission for Experimentation on Animals at Warsaw University of
Life Sciences, Poland.
Preparation and characterisation of nanocolloids
The colloid of nanoparticles of platinum was purchased from Nano-koloid (Warsaw, Poland).
This material is produced by a patented electric non-explosive method (Polish patent 380649)
from high-purity metal (99.9999%) and high-purity demineralised Milli-Q water. After 30
minutes of sonication, the solution was diluted to different concentrations with 1×Dulbecco’s
modified Eagle’s culture medium (Sigma–Aldrich, St. Louis, MO, USA), immediately prior to
exposure to GBM cells or tumour tissue.
The shape and size of the NP-Pt were inspected using a JEM-1220 (JEOL, Tokyo, Japan)
transmission electron microscope (TEM) at 80 KeV, with a Morada 11-megapixel camera
(Olympus Soft Imaging Solutions, Mu¨nster, Germany). Samples for the TEM were prepared
by placing droplets of hydrocolloids on to Formvar-coated copper grids (Agar Scientific,
Stansted, UK). Immediately after drying of the droplets in dry air, the grids were inserted into
the TEM.
The zeta potential in water was measured using a Zetasizer Nano ZS model ZEN3500 (Mal-
vern Instruments, Malvern, UK). The test was performed in triplicate.
Cisplatin (cis-diamineplatinum (II) dichloride) was obtain from Sigma (479306; Sigma,
St. Louis, MO, USA) and diluted to 20 μg/ml in ultrapure Milli-Q water, and it was diluted to
different concentrations with 1×Dulbecco’s modified Eagle’s culture medium (Sigma–
Aldrich, St. Louis, MO, USA), immediately before use. The concentration of NP-Pt was equal
to the atomic mass of Pt atoms in cisplatin. The concentration of NP-Pt was based on pub-
lished data about anticancer properties of cisplatin [16].
Cell cultures and treatments
Human glioblastoma U118 and glioblastoma likely U87 cell [17, 18] lines were obtained from
the American Type Culture Collection (Manassas, VA, USA) and maintained in Dulbecco’s
modified Eagle’s culture medium supplemented with 10% foetal bovine serum (Sigma-
Aldrich), 1% penicillin, and streptomycin (Sigma-Aldrich) at 37˚C in a humidified atmosphere
of 5% CO2/95% air in a NuAire DH AutoFlow CO2 Air-Jacketed Incubator (Plymouth, MN,
USA).
Cell morphology
U87 and U118 glioma cell lines were placed on 6-well plates (1x 105 cells per well) and treated
with NP-Pt and cisplatin after overnight incubation. After 24h of incubation, the morphology
Nanoplatinum tumour treatment
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of cells was recorded under an optical microscope (DM750; Leica Microsystems GmbH, Wet-
zlar, Germany) using LAS EZ version 2.0 software. The experiment was performed in three
repetitions (each experimental group in triplicate).
Proliferation assay by BrdU incorporation
Cell proliferation was evaluated using a bromodeoxyuridine (BrdU) incorporation assay
(BrdU colorimetric) (Roche Applied Science, Indianapolis, IN, USA). U87 and U118 cell lines
(1×104) were placed in 96-well plates and cultured overnight. After incubation, medium was
removed and hydrocolloids of NP-Pt and cisplatin were introduced to the cells for the next 24
h. Then, the culture media was removed, the cells were fixed, and the DNA was denatured in
one step by adding FixDenat. In the next step, the cells were incubated with anti-BrdU-POD
antibody for 90 minutes at room temperature. After the removal of the antibody conjugate, the
cells were washed and the substrate solution was added. The reaction product was quantified
by measuring absorbance using a scanning multi-well spectrophotometer (Infinite M200,
Tecan, Durham, NC, USA) at 370 nm with a reference wavelength of 492 nm and finally
expressed as the difference between BrdU-positive and -negative samples, expressed as Optical
Density (O.D.). All experiments were performed in three repetitions (each experimental group
in triplicate).
Cell migration assay
The cell migration assays were performed using 8-μm pore inserts (Starstedt, Nu¨mbrecht, Ger-
many) pre-coated with 0.5 μg/ml of the chemo-attractant fibronectin (Sigma). U87 cells
(5 × 104) were placed into transwell inserts in triplicate and incubated overnight. Next, the
cells were treated with NP-Pt hydrocolloid and cisplatin solution and allowed to migrate for
24h.
Migrated cells were fixed with 4% paraformaldehyde (Sigma–Aldrich) in PBS and visualised
by staining with 0.1 μg/ml DAPI (Life Technologies, Gaithersburg, MD, USA). Migration was
determined by imaging DAPI nuclear stain and viewed using a CKX 41 epifluorescent inverted
microscope (Olympus, Tokyo, Japan) with a fluorescent filter, and the image was captured
with a ProgRes c12 camera (Jenopik, Germany). The migration experiment was performed in
three repetitions (each experimental group in triplicate). The number of cells that had passed
through the membranes were counted as a measure of their migration potential.
Culture of GBM on chorioallantoic membrane
Fertilised eggs (Gallus gallus) (n = 60) were supplied by a commercial hatchery. After 6 days of
egg incubation, the silicone ring with the deposited 3–4 × 106 U87 cells suspended in 30 μL of
culture medium was placed on the chorioallantoic membrane according to the procedure
described by. Grodzik et al. [19]. The eggs were incubated for 7 days; then 36 eggs with visible
tumour development were chosen. Eggs were divided into three groups of 12: the control
group, 8.45μM/mL NP-Pt group (injected with 200 μL of solution) and 13μM/mL cisplatin
group (injected with 200 μL). The solutions were slowly injected with insulin syringe (Ø = 29
mm) under sterile conditions in a laminar chamber. The dose of cisplatin for direct intratu-
mour injection was calculated based on Cemazar et al. [20]. The concentration of NP-Pt was
equal to the atomic mass of Pt atoms in cisplatin. The solutions were added directly into the
tumours. After 2 days, the tumours were resected for further analysis.
Nanoplatinum tumour treatment
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Examination of proliferation of tumour tissue by PCNA protein
expression
The proliferating cells were identified via immunofluorescence and immunohistochemistry,
using antibody directed against proliferating cell nuclear antigen (PCNA). Glioma tumour
tissue samples from each group (n = 3 x 4) were collected and fixed for immunofluorescent
and immunohistochemistry analyses, according to standard procedures described by Prasek
et al. [15] and Urbanska et al.[21]. For fluorescence analysis, tissue samples were washed with
PBS and permeabilised with 0.5% Tween 20 (Sigma-Aldrich) PBS solution for 10 min. The
sections were blocked with PBS containing 2% of goat serum and 1% bovine serum albumin
(Sigma-Aldrich) for 30 min. Sections were incubated with primary rabbit anti-PCNA anti-
body (No. 15580, Abcam, GB) diluted in 2% goat serum for 16 h at 4˚C (according to the
manufacturer’s instructions). After PCNA localisation in gliomas tumour tissue washing sec-
tions were incubated with secondary antibody: goat anti-rabbit Atto 488 conjugate (IgG
(H+L),F(ab’)2 Fragment Atto488; Cell Signaling Technology, Danvers, USA) for 1 hrs,
diluted according to producer instructions. Nuclei were stained by incubation with 40,6-dia-
midino-2-phenylindole (DAPI) solution for 15 min (Sigma-Aldrich). After washing, the
cover slips were mounted on slides with Fluoromount mounting medium (Sigma-Aldrich)
and observed on IX 81 FV-1000 confocal microscope (Olympus Corporation, Tokyo, Japan).
Image analysis in confocal mode, Nomarski interference contrast and cell counting were per-
formed using FVIO-ASW ver. 1.7c software (Olympus). Three-dimensional images were
assembled from 30 optical sections. The sections for immunohistochemistry investigation
were incubated for 1 hour with the rabbit polyclonal anti- PCNA at room temperature, and
visualised with DAKO EnVision+System-HRP (K 4010, DAKO, Glostrup, Denmark). The
proliferation levels were expressed as the number of PCNA-positive cells in the tumour sec-
tions (counted area– 3500 μm2).
Analysis of 8-hydroxy-2’-deoxyguanosine (8-OH-dG) concentration in
tumour tissue DNA
8-HO-dG is a modified base of nucleoside and it is mainly detected as a product of oxidative
DNA damage. Samples of tumour tissue from each group (n = 3 x 4) were collected and frozen
in -80˚C. The samples were refrozen and 5 mL of homogenisation buffer (0.1 M phosphate
buffer, pH 7.4, containing 1 mM EDTA) per gram of tissue was added. Next, the homogenisa-
tion procedures were conducted according to the commercial available protocol, using Tissue-
Lyser homogeniser (86500, Qiagen, Hilden, Germany). The samples were centrifuged at 1,000
x g for 10 minutes and the supernatants were purified using a commercially available DNA
extraction kit (A1120, Promega, Madison, WI, USA).
8-OH-dG was measured in tumour tissue DNA samples, using a commercial 8-OH-dG
ELISA kit (ab201734, Abcam, Cambridge, UK) following the manufacturer’s protocol. Sam-
ples were diluted at a ratio of 1:10 of a sample to the final concentration of DNA 19.6 ng/ml,
the concentration of 8-HO-dG was measured at 450 nm.
Statistical analysis
Data were analysed using one-way analysis of variance with Statgraphics1 Plus 4.1 (StatPoint
Technologies, Warrenton, VA, USA). The differences between groups were tested using
Tukey’s multiple-range tests. All mean values are presented with the standard deviation.
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Results
NP-Pt characterisation
Fig 1 shows TEM imagines of NP-Pt. NP-Pt had regular round shape and diameter of the par-
ticles ranged from 2 nm (>60%) to 25 nm (<5%) (Fig 1). The mean zeta potential of NP-Pt
was -27.86 mV.
Cell morphology
Evaluation of U118 and U87 glioma cells by light microscopy demonstrated that U87 and
U118 gliomas cells were characterised by a different cells morphology (Fig 2). U118 cells had
smaller and less branched protrusions than U87 cells. U118 were smaller and grew much
slower than U87 cells. The administration of NP-Pt as well as cisplatin had harmful effects on
gliomas cells morphology. In every cell line the NP-Pt treatment caused the cells membrane
deformation and decreased the cells density. Cell morphology was similar in the NP-Pt and
cisplatin groups, but the treated cells lost their characteristic morphology (branched protru-
sions, shape, size) in comparison to the control group.
Fig 1. Transmission electron microscopic images of platinum nanoparticles. Bar scale 100nm.
https://doi.org/10.1371/journal.pone.0178277.g001
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Cell proliferation
BrdU is a synthetic analogue of thymidine which during the cell cycle is implemented into
DNA. The increased level of BrdU was equal to the increased cell proliferation. The U118 and
U87 cells proliferation status detected by BrdU incorporation showed that increasing concen-
tration of NP-Pt decreased the cell proliferation comparing to the control group (Table A in S1
File). According to the BrdU assay, NP-Pt had significant higher anti-proliferative activity
comparing to cisplatin, especially against U118 cell line (Table B in S1 File). The bars form Fig
2G, indicate a significantly lower average of proliferating U118 cells. The comparison of the
proliferation between the cell lines showed that U87 cells were more sensitive that U118 cells
(Fig 2).
Cell migration assay
Comparison to U87 glioma cells from the control group showed that U87 glioma cells lost
their ability for migration after NP-Pt administration (Fig 3). These results indicated that
NP-Pt administration to U87 cells affects the migration of gliomas cells with comparable effi-
ciency as cisplatin solution (Table D and Table E in S1 File).
Tumour tissue proliferation assay
The evaluation of proliferation status at tumour tissue showed that intratumoural injection of
NP-Pt hydrocolloid deceased significantly the proliferation of tumour cells. The number of
PCNA-positive cells decreased after NP-Pt administration comparing to the control (non-
treated) group (Table 1). A comparison of cisplatin treatment and NP-Pt showed that the
reduction of proliferation was lower in the cisplatin group (Table C in S1 File). These results
indicate that the proliferation and density of tumour tissue were significantly reduced after
NP-Pt treatment (Fig 4), (Fig A in S1 File).
Fig 2. Cell morphology and BrdU incorporation assay. Optical microscopy images of platinum nanoparticles (NP-Pt) or cisplatin -treated and
untreated U87 and U118 glioma cells. (A) U87 control; (B) NP-Pt—treated U87; (C) cisplatin-treated U87; (D) U118 control; (E) NP-Pt-treated U118; (F)
cisplatin-treated U118. BrdU incorporation assay–(G)–U87 cells; (H)–U188 cells. a, b Values with different letters are significantly different, P < 0.05. Bar
scale 100μm.
https://doi.org/10.1371/journal.pone.0178277.g002
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Analysis of 8-hydroxy-2’-deoxyguanosine (8-OH-dG) concentration in
tumour tissue DNA
The evaluation of 8-OH-dG level in tumour tissue showed that intratumoural injection of
NP-Pt hydrocolloid significantly increased concentration of 8-OH-dG in DNA (Fig B in S1
File, Table F in S1 File) comparing to the control (non-treated) and cisplatin group (Table 2).
The result indicate that NP-Pt efficiently cause oxidative DNA damage in tumour tissue.
Discussion
The results of the present studies indicated that NP-Pt can be an efficient inhibitor of glioma
cells proliferation. NP-Pt have fewer side effects on general health than do platinum salts such
Fig 3. U87 cell migration. Confocal fluorescent microscopy images of platinum nanoparticles (NP-Pt) or cisplatin -treated and untreated U87 glioma
cells. (A) U87 control; (B) NP-Pt—treated U87; (C) cisplatin-treated U87; (D) effect of NP-Pt on the migration of U87 glioma cells a, b Values with different
letters are significantly different, P < 0.05. Bar scale 40μm. Note: red arrows—U87 glioma cells shown as an overlaid image of 40,6-diamidino-
2-phenylindole-stained nuclei (blue). Abbreviations: C—control group.
https://doi.org/10.1371/journal.pone.0178277.g003
Table 1. Numbers of PCNA positive nuclei in glioblastoma multiforme tumour tissue (area counted 3500 μm2) in the control group and in groups
treated with platinum nanoparticles and cisplatin.
Control Platinum nanoparticles Cisplatin SE-pooled
Number of cells 199a 113b 153b 12.35
a,b Within rows: means with different superscripts differ significantly (P<0.001)
https://doi.org/10.1371/journal.pone.0178277.t001
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Fig 4. Protein expression level of PCNA at U87 glioma tumour tissue. Visualization of PCNA via immunohistochemistry (A, B, C) and
immunofluorescence (D, E, F, G, H, I) in glioblastoma tumours. (A), (D), (G)- U87 control; (B), (E), (H)- NP-Pt—treated U87; (C), (F), (I)- cisplatin-treated
U87. Scale bars: 50 μm. Note: white arrows point to PCNA positive nuclei.
https://doi.org/10.1371/journal.pone.0178277.g004
Table 2. Formation of 8-HO-dG in nuclear DNA of human gliblastoma multiforme tumour tissue cells treated with platinum nanoparticles and
cisplatin.
Control Platinum nanoparticles Cisplatin SE-pooled
8-HO-dG concentration [pg/mL] 180.9a 383.2b 204.1a 14.78
a,b Within rows: means with different superscripts differ significantly (P<0.0001)
https://doi.org/10.1371/journal.pone.0178277.t002
Nanoplatinum tumour treatment
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as cisplatin and localise primarily at target/specific cells or tissues [6, 21 – 22]. Moreover, the
size <20 nm of NP-Pt determines their bioavailability for cells and tissue and improves the
NP-Pt uptake by cancer cells [6–7, 9, 12, 22]. The inhibition of proliferation processes is crucial
to patient treatment in the dynamic fields of oncology, especially neurooncology, where the
downregulation proliferation of cancer cells is crucial for the success of treatment [23]. The
obtained results showed that NP-Pt can affect proliferation of glioblastoma cells and tissue.
The incorporation of BrdU into the DNA helix showed that NP-Pt treatment decreased the
proliferation of U87 and U118 cells and also caused morphological deformations (dwindled
cytoplasmic protrusions). Furthermore, this dose-dependent toxicity showed that NP-Pt treat-
ment decreased cell migration, which affects the malignancy of U87 glioma tumours. In addi-
tion, evaluation of the migration potential of glioma cells provided information about the
influence of NP-Pt on metastasis at tumour tissue, indicating that NP-Pt treatment, as well as
cisplatin can reduce the metastasis of glioblastoma tumour cells by reducing the number of cir-
culating tumour cells in the bloodstream. Our previous report demonstrated that NP-Pt had
anticancer properties and increased the apoptosis of glioma cells and tumour tissue[6]. While
in the present experiments, we demonstrated that NP-Pt and cisplatin decreased cell migra-
tion, indicating that both Pt treatments can reduce the metastasis of glioblastoma tumour cells
by reducing the number of circulating cells in the bloodstream. NP-Pt were also able to arrest
the cell cycle and caused apoptosis of U251 glioma cells [10]. However, the U251 and U87 glio-
blastoma cell lines are different regarding proliferation, invasion and migration ability. More-
over, comparing protein expression between U251 and U87 cell lines, the U251 has 263
proteins that have a lower level of expression comparing to the U87 line [24]. Therefore, these
proteins are involved in a drug resistance, because the drugs that target the purine metabolism
are more toxic to U251 than U87 cell line. Additionally, the U251, U87 and U118 have also dif-
ferent genetic mutations (p53, p21, CDKN2A, PTEN) which affect anticancer properties of
platinum-based drugs.
The invasion of glioma cell into brain tissue structure is caused by interactions with
extracellular matrix and modification of cancer cell morphology including prolongation of
protrusions, which become an anchor and allowing interactions between glioma cells and
cytoskeleton [24]. The results of in vitro experiments showed that NP-Pt treatment was as
efficient as cisplatin in terms of changes in cell morphology, proliferation, and migration.
Platinum-based anticancer drugs such as cisplatin, carboplatin or oxaliplatin are commonly
used to treat several types of cancer like: head and neck, lung, colorectal cancer and other solid
tumours [25]. The main mechanism of the anticancer activity of platinum salts is based on the
formulation of cisplatin-DNA adducts as a result of mismatch repair and cellular levels of
damage-recognition proteins [26]. However, the major drawbacks of platinum-based cancer
chemotherapy are neurotoxicity, nephrotoxicity, ototoxicity and limited efficiency caused by
developed chemoresistance of cancer cells [27]. Recent studies showed that the intratumoural
injection of NP-Pt decreased PCNA protein expression in glioma tumours. PCNA is a 36 kDa
molecular weight non–histamine nuclear protein, which expression occurs only in proliferat-
ing cells. The increased level of PCNA expression is mainly observed during G1 and S phase of
the cell cycle and contributes to DNA replication [4]. The evaluation of PCNA expression is
significant in terms of the determination of malignancy, metastasis and tumour grade [28].
Moreover, PCNA is also the basic component of recombination-associated DNA synthesis
during the process of double-strand break repair in chemoresistant cancer or after treatment
with platinum-based cancer drugs [29–30]. Previous studies of PCNA protein expression levels
in astrocytoma and oligoastrocytoma indicated that increased expression was correlated with
increasing tumour grade [29] and decreasing patient survival rates [31–33]. In the present
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study, we found that the protein expression of PCNA was significantly lower in the treated
tumour samples than in the control. Our results are similar to previous results about the anti-
cancer properties and antiproliferative properties of nanoplatinum, where NP-Pt of 5–8 nm in
size mediated cell growth arrest, downregulated PCNA protein expression and activated apo-
ptosis in U251 glioma cells [10]. The observation of in ovo glioma model also showed that sin-
gle-dose injection of NP-Pt stayed locally, and exudation of NP-Pt from tissue samples or
general toxicity to chicken embryos was not detected. The in ovo model of glioblastoma
tumour meets criteria for the xenograft model of glioblastoma including sufficiently similar
protein expression panel comparing to the nude rat models [34], easy access to the tumour tis-
sue, time controlled growth, and a low cost. Moreover, the in vivo models for brain tumour
growth should be developed from glial cells, and their growth should be also predictable and
reproducible. Strojnik et al. [34] described the in ovo and in vivo U87 glioblastoma tumour,
and in both models, authors observed the typical cytological structure of glioma tumour
including the presence of astrocytes, small anaplastic cells, spindle and giant cells. On the
other hand, the major issue with in ovo models, is limited observation of infiltrative growth of
glioblastoma tumour into brain structure. Currently, authors conduct investigations using in
vivo rat model to confirm in ovo results, but the data still need to be elucidated in follow-up
studies.
In vivo anticancer activity of NP-Pt was also observed in a glioblastoma rat model, where
nanosized platinum had a negative impact on vascularisation and decreased tumour tissue
growth [13]. The anticancer properties of NP-Pt induce DNA damage, caused by the interac-
tion between the OH groups on the NP-Pt surface with phosphate groups on the DNA helix
[12]. In the present study the evaluation of 8-HO-dG concentration after NP-Pt treatment
demonstrated that NP-Pt have a strong affinity to DNA, thus, NP-Pt can be considered as a
new type of antineoplastic agents. Furthermore, anticancer properties of NP-Pt involve cell-
cycle inhibition by Pt2+ ions released from NP-Pt after interactions between NP-Pt and hydro-
gen peroxide in endosomes [10,12]. The main mechanism of proliferation inhibition by NP-Pt
may be caused by the bidirectional interaction of Pt+ ions with the cytoskeleton of cancer cells
or the formation of DNA strand breaks [6–7]. The results, also pointed on the antiproliferative
properties of NP-Pt, caused by degradation of NP-Pt surface and release of Pt+ ions, which
may generate the oxidative stress, affect the DNA damage and consequently decrease the pro-
liferation of tumour glioma cells. The results of the present study on U87 and U118 glioma cell
lines and tumour tissue are in agreement with previous studies with other cancers, demon-
strating that NP-Pt treatment has antiproliferative properties against HT29 human colon car-
cinoma [8], SiHa cervical cancer [35] and U251 glioblastoma [10]. The possible mechanism of
action of NP-Pt against U87 and U118 glioblastoma cells is mainly related to DNA damage by
NP-Pt attachment into DNA and formation of DNA strand breaks, which was confirmed by
the production of 8-OH-dG in glioma tumour tissue. Moreover, this mechanism is directly
correlated with the decrease of PCNA activity and consequently the decrease of cell prolifera-
tion, caused probably by arrest of DNA synthesis at S phase of cell cycle. Comparing the anti-
proliferating efficiency of cisplatin against U87 the in vitro investigation showed that NP-Pt
had a better antiproliferative efficiency than cisplatin. The in ovo measurements also revealed
that NP-Pt had a better antiproliferating efficiency against U87 tumour tissue than cisplatin, at
the same concentration of Pt atoms. Thus, the results indicate that NP-Pt may be used in glio-
blastoma cancer therapy as inhibitors of tumour cell proliferation, but the mechanism of
action and potential side effects, as well as glioma cells line characterisation, need to be eluci-
dated in the follow-up research.
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Conclusions
The in vitro investigation demonstrated that NP-Pt had antiproliferative effects on U87 and
U118 glioma cells. The U87 glioma cells treated with NP-Pt showed morphological deforma-
tions, decreased proliferation, and were more sensitive to NP-Pt treatment than U118 glioma
cells. The in ovo studies showed that NP-Pt treatment decreased PCNA protein expression
level. The measurements also revealed that NP-Pt caused oxidative DNA damage in tumour
tissue to a higher degree than cisplatin. The results indicate that NP-Pt may be used in glioblas-
toma cancer therapy. However, potential side effects must be elucidated in in vivo future
research.
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